News for Healthier Living

ASH 2025: New Combination Approach Aims to Make CAR T More Durable in Lymphoma

EMBARGOED: A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma. Findings to be presented at ASH Dec. 8, 2025.

December 8, 2025


December 13 2025

December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025